Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLO1 | Q04760 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 6/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 8/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.52 |
| ▸ | RAB9A | P51151 | 4/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | RAB7A | P51149 | 2/20 | 0.52 |
| ▸ | NOD1 | Q9Y239 | 5/20 | 0.50 |
| ▸ | TNF | P01375 | 4/20 | 0.50 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | MITF | O75030 | 1/20 | 0.50 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.50 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21261092 | 0.89 | GLO1 (0.72) | GLO1MAPTALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL21247395 | 0.87 | GLO1 (0.56) | GLO1MAPTALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL21247339 | 0.86 | MEN1 (0.69) | GLO1MAPTALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL22680862 | 0.85 | MEN1 (0.69) | GLO1MAPTALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL21247392 | 0.85 | RAB7A (0.68) | MAPTALDH1A1SMN1; SMN2LMNAHPGD | |
| SCHEMBL21261120 | 0.83 | MEN1 (0.51) | GLO1MAPTALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL21247261 | 0.82 | GLO1 (0.50) | GLO1MAPTALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL21247268 | 0.80 | NOD1 (0.69) | GLO1MAPTALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL21260924 | 0.79 | MEN1 (0.74) | GLO1MAPTALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL21247382 | 0.77 | RAB7A (0.80) | MAPTALDH1A1SMN1; SMN2LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11492347-B2 | Fused thiophene derivatives and their uses | ENYO PHARMA (FR) | 2022-11-08 | — | — | US | disclosed |
| EP-3749659-A1 | FUSED THIOPHENE DERIVATIVES AND THEIR USES | ENYO Pharma (FR) | 2020-12-16 | — | — | EP | disclosed |
| US-20200361924-A1 | FUSED THIOPHENE DERIVATIVES AND THEIR USES | ENYO PHARMA (FR) | 2020-11-19 | — | — | US | disclosed |
| US-20200361924-A1 | FUSED THIOPHENE DERIVATIVES AND THEIR USES | ENYO PHARMA (FR) | 2020-11-19 | — | — | US | disclosed |
| WO-2019154950-A1 | FUSED THIOPHENE DERIVATIVES AND THEIR USES | ENYO PHARMA (FR) | 2019-08-15 | — | — | WO | disclosed |
| WO-2019154950-A1 | FUSED THIOPHENE DERIVATIVES AND THEIR USES | ENYO PHARMA (FR) | 2019-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361924-A1 | FUSED THIOPHENE DERIVATIVES AND THEIR USES | FTH1, SLC40A1, FECH | GLO1 616/4885MAPT 2107/4885ALDH1A1 2143/4885 |
| US-11492347-B2 | Fused thiophene derivatives and their uses | FTH1, SLC40A1, FECH | GLO1 616/4885MAPT 2107/4885ALDH1A1 2143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.